Reset filter
Trefwoorden
D016430 ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
    1. 7.1. Anesthesie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Geriatrie
    1. 7.5. Gynaecologie/Ostetrie
    1. 7.6. Interne geneeskunde
      1. Hematologie
      1. Epidemiologie
      1. Cardiologie/Angiologie
      1. Pneumologie
      1. Gastro-enterologie
      1. Nefrologie
      1. Endocrinologie/Metabolisme
      1. Rheumatologie
    1. 7.7. Neurologie
    1. 7.8. Oogheelkunde
    1. 7.9. Palliatieve zorg
    1. 7.10. Pathologie/Forensische Geneeskunde
    1. 7.11. Kindergeneeskunde
    1. 7.12. Psychiatrie/Psychosomatisch
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Algemene/maag-darm-chirurgie
      1. Neurochirurgie
      1. Plastische chirurgie
      1. Cardiothoracale chirurgie
      1. Traumachirurgie/Orthopedie
      1. Vaatchirurgie
    1. 7.15. Urologie
    1. 7.16. Tandheelkunde/MKG
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

2405 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Eligibility Lymphoma, Non-Hodgkin NCT00322387

- 15-10-16 - 1 Formulier, 1 Itemgroep, 14 Data-elementen, 1 Taal
Itemgroep: Criteria
Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00322387

Eligibility B-cell Non Hodgkin Lymphoma NCT01516580

- 19-08-19 - 1 Formulier, 2 Itemgroepen, 18 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01516580

Eligibility Non-Hodgkin Lymphoma NCT02280785

- 24-05-19 - 1 Formulier, 2 Itemgroepen, 35 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
To Assess the Efficacy of Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02280785

Eligibility Lymphoma, Non-Hodgkin NCT02431403

- 03-05-19 - 1 Formulier, 2 Itemgroepen, 19 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02431403

Eligibility Lymphoma, Non-Hodgkin NCT01996865

- 02-05-19 - 1 Formulier, 2 Itemgroepen, 15 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.; ODM derived from: https://clinicaltrials.gov/show/NCT01996865

Eligibility Leukemia NCT00469820

- 03-08-17 - 1 Formulier, 1 Itemgroep, 15 Data-elementen, 1 Taal
Itemgroep: Criteria
Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant; ODM derived from: https://clinicaltrials.gov/show/NCT00469820

Eligibility Non-Hodgkin Lymphoma NCT00626444

- 17-07-18 - 1 Formulier, 2 Itemgroepen, 18 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL); ODM derived from: https://clinicaltrials.gov/show/NCT00626444

Eligibility Non-Hodgkin Lymphoma NCT00429065

- 17-07-18 - 1 Formulier, 2 Itemgroepen, 15 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.; ODM derived from: https://clinicaltrials.gov/show/NCT00429065

Eligibility Non-Hodgkin Lymphoma NCT00384150

- 17-07-18 - 1 Formulier, 1 Itemgroep, 13 Data-elementen, 1 Taal
Itemgroep: Criteria
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL); ODM derived from: https://clinicaltrials.gov/show/NCT00384150

Eligibility Lymphoma, Non-Hodgkin NCT01148173

- 04-06-18 - 1 Formulier, 2 Itemgroepen, 18 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT01148173

Eligibility Lymphoma, Non-Hodgkin NCT00644124

- 04-06-18 - 1 Formulier, 2 Itemgroepen, 13 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00644124

Eligibility Non-Hodgkin Lymphoma NCT00644371

- 16-08-17 - 1 Formulier, 2 Itemgroepen, 26 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Allogenic Stem Cell Transplantation (SCT) With Non-Myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL); ODM derived from: https://clinicaltrials.gov/show/NCT00644371

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial